Mistral Ventures Inc (PINK:MILV) closed at $0.014 per share last week, up 9.4% from its Thursday’s level. As it is, the latter was enough to induce third parties to launch a promotional campaign to give MILV stock a further boost today.
As many as $40 thousand dollars appear to have been spent on a single email which reached our promotional database yesterday at noon. In addition, the company has just announced that its wholly owned subsidiary, Nature Bioceuticals, would take part in the Natural Products Expo West trade show scheduled for March 2012 to showcase its new products. In short, MILV stock has virtually received as much support for today’s market session as possible.
Nature Bioceuticals specializes in developing natural medicine formulas for the treatment of specific medical conditions. Thus, the company aims to provide an alternative to conventional synthetic drugs which is just as effective. At this stage, it is not quite clear whether the company’s press releases are indicative of real progress or they convey nothing but delusions of grandeur.
MILV’s interim financial report for the quarter ended Sept. 30, 2011 revealed:
- cash reserves of $4,600;
- working capital deficit of $113K;
- quarterly net loss of $36K;
- cumulative net loss of $246K for the fiscal year ended Dec. 31, 2010.
Needless to say, a company in such a frail financial condition could only attract investors’ attention for a short while. That is why, to achieve long-term sustainable growth on the charts, it will take more than bombastic PRs to set the wheels in motion.
